化学
纳米载体
前药
药物输送
细胞周期
体内
细胞周期检查点
活性氧
阿霉素
紫杉醇
药理学
细胞
化疗
生物化学
医学
生物技术
外科
有机化学
生物
作者
Yu Sun,Qing Wu,Qiang Fu,Hailin Cong,Youqing Shen,Bing Yu,Hao Hu
出处
期刊:Talanta
[Elsevier]
日期:2024-01-01
卷期号:267: 125242-125242
被引量:1
标识
DOI:10.1016/j.talanta.2023.125242
摘要
Combination chemotherapy is a common strategy to enhance treatment efficacy and avoid multidrug resistance (MDR) in clinical practice. However, it is difficult to ensure the co-enrichment and reasonable ratio of synergistic drugs in the lesion site after intravenous administration. Integrating synergistic drugs into a nanocarrier can improve drug stability, targeting, drug loading, and importantly, ensure that synergistic drugs work at one destination. This study uses 10-hydroxycamptothecin (HCPT) to construct a polymeric prodrug micelle, and the demethylcantharidin (DMC) is proportionally encapsulated within the micelle. Triggered by reactive oxygen species (ROS), HCPT and DMC were released simultaneously from the co-delivery platform in tumor cells. DMC promotes abnormal cell division by inhibiting the synthesis of the cell cycle checkpoint kinase Protein phosphatase 2A (PP2A), leading to increased cell vulnerability to DNA damage, disordered replication, and death. The co-delivery platform exhibited satisfactory biosafety and antitumor efficacy in vivo. The proposed co-delivery platform may provide a valuable reference for the translation of clinical combination chemotherapy regimens into nano-drug delivery systems.
科研通智能强力驱动
Strongly Powered by AbleSci AI